| Dr Michael W Nielsen, DPM | |
|
4501 Sand Creek Rd, Antioch, CA 94531-8687 | |
| (925) 813-3450 | |
| Not Available |
| Full Name | Dr Michael W Nielsen |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 14 Years |
| Location | 4501 Sand Creek Rd, Antioch, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952608077 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | EF078 (California) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | T-1033 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - Antioch | Antioch, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Levels of pain severity from ear aches observed and reported by parents of preverbal children can be influenced as much by socioeconomic status and other non-clinical factors as symptoms unless physicians ask about specific observable symptoms, according to research in The Journal of Pain, published by the American Pain Society.
Thoracic surgeon Daniel Bethencourt, MD, one of the few cardiac surgeons to cure atrial fibrillation (rapid, irregular heartbeat) without opening the patient's chest, will perform endoscopic microwave ablation to treat atrial fibrillation in a 59-year-old man
A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,-an MSKCC surgeon, researcher and the Director of the Brain Tumor Center-and was published in the October 1 issue of the journal Genes & Development.
› Verified 1 days ago
| Provider Name | Permanente Medical Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Levels of pain severity from ear aches observed and reported by parents of preverbal children can be influenced as much by socioeconomic status and other non-clinical factors as symptoms unless physicians ask about specific observable symptoms, according to research in The Journal of Pain, published by the American Pain Society.
Thoracic surgeon Daniel Bethencourt, MD, one of the few cardiac surgeons to cure atrial fibrillation (rapid, irregular heartbeat) without opening the patient's chest, will perform endoscopic microwave ablation to treat atrial fibrillation in a 59-year-old man
A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,-an MSKCC surgeon, researcher and the Director of the Brain Tumor Center-and was published in the October 1 issue of the journal Genes & Development.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael W Nielsen, DPM 2163 Concord Ave, Brentwood, CA 94513-4711 Ph: (916) 597-6358 | Dr Michael W Nielsen, DPM 4501 Sand Creek Rd, Antioch, CA 94531-8687 Ph: (925) 813-3450 |
News Archive
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.
Levels of pain severity from ear aches observed and reported by parents of preverbal children can be influenced as much by socioeconomic status and other non-clinical factors as symptoms unless physicians ask about specific observable symptoms, according to research in The Journal of Pain, published by the American Pain Society.
Thoracic surgeon Daniel Bethencourt, MD, one of the few cardiac surgeons to cure atrial fibrillation (rapid, irregular heartbeat) without opening the patient's chest, will perform endoscopic microwave ablation to treat atrial fibrillation in a 59-year-old man
A multi-institutional team led by investigators from Memorial Sloan-Kettering Cancer Center has published a study that provides new insight into genetic changes that make some forms of glioblastoma, the most common type of primary brain cancer, more aggressive than others and explains why they may not respond to certain therapies. The research was led by senior author Eric C. Holland, MD, PhD,-an MSKCC surgeon, researcher and the Director of the Brain Tumor Center-and was published in the October 1 issue of the journal Genes & Development.
› Verified 1 days ago
Dr. Wen-yin Choi, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 4053 Lone Tree Way, Antioch, CA 94531 Phone: 510-610-3618 | |
Dr. Edward Youn, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 4053 Lone Tree Way Ste 200, Antioch, CA 94531 Phone: 925-776-7725 Fax: 510-506-7728 | |
Dr. James Roy Boccio, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 3700 Sunset Ln, Suite 1, Antioch, CA 94509 Phone: 925-778-2977 Fax: 925-778-6173 | |
Xingbo P Sun Podiatrist Medicare: Medicare Enrolled Practice Location: 3700 Sunset Ln Ste 1, Antioch, CA 94509 Phone: 925-979-8313 Fax: 025-954-6959 | |
Dr. Dennis M Osborne, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1205 A St, # 4, Antioch, CA 94509 Phone: 925-778-1800 Fax: 925-778-1877 |